|
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355
|
BEIJING, Sept. 17, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the Investigational New Drug (IND) of CM355, a CD20xCD3 bispecific antibody develo...
Full "IntellAsia: Resources" article
|
|